New iPad App from Pubget Streamlines Access to Published Scientifc Literature

Boston, MA (PRWEB) September 21, 2011

Today, Pubget announces the release of Pubget for the iPad. The app was built to bring Pubget.com's streamlined approach to searching, finding and saving papers to Apple's game-changing device.

Unlike similar apps, Pubget does not require researchers to build a library of articles beforehand and upload them to the device. Instead, Pubget instantly connects researchers to over 30 million PDFs "cloud sourced" through the library at their school or work. The app is built upon the proven article retrieval technology developed as part of, pubget.com over the past four years.

"Scientists' demand for portability inspired us to optimize Pubget for the iPad," said Mike Anderson, Director of Products at Pubget. "After thousands of development hours, we're excited to literally get this into the hands of the scientific community."

Sigma Life Science, a global leader in providing the life science community with products and technologies that can accelerate research, has collaborated with Pubget to develop the app's concept and bring it to market. Anderson continues, "We are excited to be working so closely with Sigma, as their positive reputation and drive to bring more efficient research to scientists aligns with our objectives. Together, we are helping discoveries move at an awesome pace ­- from published research to the benchtop."

The Pubget app is free and available for download on the App Store as of this release. Its full text content feed is currently supported for over 450 research institutions worldwide. To learn more, go to http://corporate.pubget.com/ipad.

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.